Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta‐analysis‐based comparison of treatment efficacy

医学 荟萃分析 置信区间 掌跖脓疱病 随机对照试验 优势比 梅德林 分级(工程) 系统回顾 随机效应模型 内科学 物理疗法 皮肤病科 银屑病 工程类 土木工程 政治学 法学
作者
Takemichi Fukasawa,Takashi Yamashita,Atsushi Enomoto,Asako Yoshizaki‐Ogawa,Kiyoshi Miyagawa,Shinichi Sato,Ayumi Yoshizaki
出处
期刊:Journal of The European Academy of Dermatology and Venereology [Wiley]
卷期号:38 (2): 281-288 被引量:5
标识
DOI:10.1111/jdv.19499
摘要

Few studies have made direct comparisons between treatments for palmoplantar pustulosis (PPP); therefore, it is difficult to select the best treatment for each patient. To determine the best therapy and to compare reported measures of efficacy in clinical trials of systemic treatments for PPP in this systematic review and network meta-analysis. Six databases were used to perform database search on 10 July 2022. Randomized controlled trials (RCTs) were identified through a systematic literature search. The titles and abstracts of articles were initially screened for inclusion by two authors independently using our predetermined criteria. The full texts of selected articles were then independently assessed for inclusion in a blinded fashion. Disagreement between the authors was resolved by consensus. Data were abstracted in duplicate. Random-effects model was accepted to perform network meta-analysis. Assessed Grading of Recommendations Assessment, Development and Evaluation certainty of evidence were performed according to the PRISMA guidelines. The analysis was completed in July 2022. The primary outcome was the change of PPP Area and Severity Index (PPPASI) from baseline and the secondary outcome was the achievement of PPPASI-50 response. Seven RCTs with 567 patients were included. Guselkumab 100 mg was the one with the highest probability of reaching the proposed outcomes (mean difference [MD], -8.00; 95% confidence interval [CI], 4.88-11.11), while the achievement of PPPASI-50 response did not show a significant difference (odds ratio [OR], 3.79; 95% CI, 0.51-28.37). Guselkumab 200 mg was next to 100 mg of reaching the proposed outcomes (MD, -4.71; 95% CI, 2.12-7.30), while the achievement of PPPASI-50 response did not show a significant difference (OR, 2.34; 95% CI, 0.48-11.43). Network meta-analysis showed guselkumab 100 mg was the treatment with the highest probability of reaching both PPPASI and PPPASI-50 outcomes. Absolute PPPASI may be more appropriate as an outcome than PPPASI-50.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
辛勤自行车完成签到,获得积分10
1秒前
斯文败类应助aran采纳,获得10
2秒前
2秒前
Jasen发布了新的文献求助10
4秒前
魏欣娜完成签到 ,获得积分10
5秒前
张欢馨应助阿飞采纳,获得10
6秒前
fangyuan发布了新的文献求助10
7秒前
千与千寻发布了新的文献求助10
7秒前
8秒前
8秒前
9秒前
10秒前
沉默不评完成签到,获得积分10
11秒前
lll完成签到,获得积分20
11秒前
TIZI完成签到,获得积分10
11秒前
momo完成签到,获得积分10
11秒前
xinxin关注了科研通微信公众号
11秒前
天天快乐应助细胞1采纳,获得10
11秒前
12秒前
kk发布了新的文献求助10
12秒前
二分三分完成签到,获得积分0
13秒前
duoduo完成签到,获得积分10
13秒前
元2333发布了新的文献求助10
14秒前
不想上学发布了新的文献求助10
14秒前
shengyina发布了新的文献求助30
15秒前
lll发布了新的文献求助30
15秒前
Jasper应助fengwanru采纳,获得10
15秒前
星辰大海应助fangyuan采纳,获得10
16秒前
16秒前
阿愿完成签到,获得积分10
17秒前
17秒前
Jasen完成签到,获得积分10
18秒前
Correna应助qq采纳,获得10
19秒前
小小发布了新的文献求助10
19秒前
20秒前
20秒前
lililo314发布了新的文献求助10
22秒前
张无凡完成签到,获得积分10
22秒前
年糕完成签到,获得积分10
24秒前
周阳完成签到 ,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Römisch-Germanische Forschungen 1000
APA handbook of comparative psychology: Basic concepts, methods, neural substrate, and behavior 1000
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
The fast track to determining transfer functions of linear circuits: The student guide 500
The Analytical and Numerical Solution of Electric and Magnetic Fields 500
Discerning Saints: Moralization of Intrinsic Motivation and Selective Prosociality at Work 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7607684
求助须知:如何正确求助?哪些是违规求助? 9183665
关于积分的说明 19670626
捐赠科研通 7181846
什么是DOI,文献DOI怎么找? 3269869
关于科研通互助平台的介绍 2433616
邀请新用户注册赠送积分活动 2264238